



HAL
open science

On hepatocellular carcinoma in South America and early-age onset of the disease

Pascal Pineau, Eloy Ruiz, Eric Deharo, Stephane Bertani

► **To cite this version:**

Pascal Pineau, Eloy Ruiz, Eric Deharo, Stephane Bertani. On hepatocellular carcinoma in South America and early-age onset of the disease. *Clinics and Research in Hepatology and Gastroenterology*, Elsevier, 2019, 43 (5), pp.522-526. 10.1016/j.clinre.2018.10.019 . pasteur-02641989

HAL Id: pasteur-02641989

<https://hal-pasteur.archives-ouvertes.fr/pasteur-02641989>

Submitted on 20 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International License

1 **On hepatocellular carcinoma in South America and early-age onset of**
2 **the disease**

3

4 Pascal Pineau^{1*}, Eloy Ruiz², Eric Deharo³, Stéphane Bertani^{3*}

5

6 ¹ Institut Pasteur, Unité Organisation Nucléaire et Oncogénèse, INSERM, U
7 993, Paris, France

8 ² Instituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía
9 en Abdomen, Lima, Peru

10 ³ Université de Toulouse, IRD, UPS, UMR 152 PHARMADEV, Toulouse,
11 France

12 *Correspondence: P.P. (email: pascal.pineau@pasteur.fr) and S.B.
13 (stephane.bertani@ird.fr)

14

15 **Summary**

16 Hepatocellular carcinoma (HCC) is one of the most predominant tumor types
17 worldwide, being particularly prevalent in sub-Saharan Africa and East Asia.
18 However, HCC is inexplicably underreported in South America, despite
19 unsettling clinical epidemiological trends of the disease on this continent.
20 Here, we review the current knowledge on HCC presentation in Peru. We
21 emphasize the well documented occurrence of an early-age nosological form
22 of the disease in Andean descent populations. We further discuss the reasons
23 for such clinical presentation, as well as the implications for liver cancer
24 screening, management, and prevention.

25

26 **Keywords**

27 Liver cancer; Cancer risk factor; Hepatitis B virus (HBV); Indigenous people;
28 Low- and middle-income countries; Global health transition

29

30 **Abbreviations**

31 AFP, alpha-fetoprotein; CELAC, Community of Latin American and Caribbean
32 States; HBV, Hepatitis B virus; HBsAg, HBV surface antigen; HCC,
33 Hepatocellular carcinoma; HCV, Hepatitis C virus; INEN, National Cancer
34 Institute of Peru

35

36 **Introduction**

37 Hepatocellular carcinoma (HCC), the main form of primary liver cancer, is the
38 seventh most common malignancy in incidence and the third leading cause of
39 tumor-related death in the world [1]. Global clinical epidemiology of HCC
40 reported hitherto chiefly delineates a prominent patient profile corresponding
41 grossly to males over 45 years old with chronic liver diseases [2]. The
42 incidence rate of HCC has doubled worldwide during the last two decades,
43 with nearly 85% of the recorded cases and highest rates of disability-adjusted
44 life-years occurring in low- and middle-income countries [3–5]. The largest
45 burdens of HCC are borne in sub-Saharan Africa and East Asia, where the
46 highly endemic chronic infection with hepatitis B virus (HBV) and dietary
47 exposure to mutagenic aflatoxins potentialize one another [6,7]. In contrast,
48 the incidence of HCC observed in more economically developed countries is
49 associated most of all with hepatitis C virus (HCV) infection and heavy alcohol
50 intake that are often associated with comorbid conditions, such as non-
51 alcoholic fatty liver disease, diabetes mellitus, hereditary hemochromatosis or
52 even α -1 antitrypsin deficiency [6,8–10]. These risk factors trigger overtime
53 liver cirrhosis that progresses in a significant proportion of cases in a hepato-
54 carcinogenic process.

55

56 Reviews of the global burden of liver cancer have repetitively overlooked the
57 epidemiology of the disease in South America creating a gap between the
58 existing situation in the field and the overall clinical epidemiology of HCC
59 described in the relevant literature [2,11]. Yet, while the incidence rate of
60 primary liver cancer in South America is considered low to intermediate, the

61 epidemiological trends and the clinical presentation of HCC on this continent
62 are displaying striking and worrying features as a whole. For example, South
63 America is part of the Community of Latin American and Caribbean States
64 (CELAC), which is the world region with the greatest incidence rise for liver
65 cancer monitored during the last decade [12]. Furthermore, some physicians
66 have reported on the continent, since the seventies, the dual occurrence of an
67 early-onset form of HCC in younger individuals concomitantly with a more
68 conventional older patient population.

69

70 **Clinical epidemiological peculiarities and historical background**

71 In the first instance, Donayre and colleagues reported in a cohort of 60
72 Peruvian HCC patients between 1969 and 1997 a mean age of 45 years old,
73 with as many individuals in their third decade as people in their seventh
74 decade [13]. The gender ratio (Male:Female) was balanced at 1.3, which
75 appears to be another peculiarity of the clinical epidemiology of HCC in South
76 America compared with elsewhere where the disease afflicts significantly
77 many more men than women [14]. Forty-five percent of the patients were
78 seropositive for the HBV surface antigen (HBsAg). Unfortunately, no formal
79 diagnosis of cirrhosis was provided in this study. However, the authors
80 consistently described an extensive hepatomegaly due to the explosive
81 development of HCC in a short timescale as the predominant feature of
82 clinical presentation.

83

84 Second, our group of medical practitioners and researchers described the
85 clinical and demographic features of 232 consecutive patients who underwent

86 liver resection for HCC between 1990 and 2006 at the National Cancer
87 Institute of Peru (INEN) [15]. In this cohort, the data were consistent with the
88 observations made previously by Donayre and colleagues: the gender ratio
89 was 1.5 and the mean and median ages were relatively young with 41.4 and
90 36 years old, respectively. Forty-four percent of the patients were HBsAg
91 seropositive [HBsAg(+)], and individuals presented with an extended
92 hepatomegaly due to the development of sizeable HCC of 15 cm-diameter on
93 average. Surprisingly, only 16.3% of the patients had cirrhosis, and the serum
94 level of alpha-fetoprotein (AFP) was exceedingly high with a mean value over
95 100,000 ng/mL.

96

97 Building on these studies, and in order to provide further insight into this
98 intriguing clinical epidemiological situation, we assembled the largest cohort to
99 date in South America; 1,541 Peruvian patients who were consecutively
100 diagnosed with HCC at INEN between 1997 and 2010 [16]. A comprehensive
101 analysis of the demographics substantiated that both mean and median ages
102 observed were misleading and resulted, in fact, from a genuine bimodal
103 Gaussian age-based distribution with a first peak at age 25 and a second
104 peak at age 64, each mode integrating 50% of the overall patient population
105 (Bimodality Index: 1.95; Moment of Mixture: 44.8 years old; Skewness
106 Coefficients: +0.4 and -0.6, respectively).

107

108 This age-based dispersion delineated two distinct subpopulations of HCC
109 patients with specific clinical features in terms of, *inter alia*, gender balance,
110 tumor size, distant metastasis and recurrence [16]. For example, 71% of the

111 younger patient individuals were HBsAg(+) compared with 22.5% in the older
112 patient population. As mentioned above, two remarkable hallmarks of HCC
113 clinical presentation in Peru were the significant sizing of an intrahepatic
114 tumor and the overall low frequency of associated cirrhosis in only 10% of the
115 cases examined, this ratio barely reaching 5% in the younger patient
116 population. Noticeably, AFP serum concentration was dramatically heightened
117 in the younger patient group compared with the older one, culminating with c.
118 380,000 ng/mL on average. Taken together, these findings support the idea
119 that a singular biological process is driving liver tumorigenesis in a fraction of
120 HCC patients in South America; and the clinical context described herein is
121 uniquely concerning enough to be an important research topic.

122

123 Afterward, investigators originating from a broad consortium of regional
124 countries have recently conducted a multicenter study in six South American
125 countries including Argentina, Brazil, Colombia, Ecuador, Peru, and Uruguay.
126 In two different articles analyzing the dataset collected from 1,336 patients
127 with HCC between 2005 and 2015, they corroborated at an upper regional
128 level the peculiarities of the disease originally observed in the Peruvian HCC
129 patient population; unfortunately, though, they did not refer to the works
130 previously published on this specific issue [17,18]. In their studies, the authors
131 highlighted the large proportion of HCC diagnosed below age 50 in South
132 America, notably in Peru, and correlated here again the occurrence of early
133 age HCC with a high prevalence of HBV and mild pervasiveness of
134 associated cirrhosis. In a subsequent scientific correspondence, Debes
135 suggested environmental toxins as a foe on early-age HCC in South America,

136 pointing out the putative role of dietary aflatoxin exposure as already
137 described in Africa [19,20].

138

139 **Mutation spectrum**

140 For our part, we undertook in a second phase a molecular analysis of nine
141 HCC-related gene mutation hotspots (*i.e.*, *ARID2*, *AXIN1*, *BRAF*, *CTNNB1*,
142 *NFE2L2*, *H/K/N-RAS*, and *TP53*) in 80 Peruvian HCC patients in furtherance
143 to deepen our understanding of HCC in South America [21]. We
144 demonstrated therein that Peruvian HCC featured a peculiar pattern of
145 somatic mutations. The number of genetic alterations observed within these
146 mutational hotspots was relatively low (0 to 3 per tumor) and the intensity of
147 the mutagenic process rather mild with only two mutation hotspots (*i.e.*,
148 *CTNNB1* and *TP53*) reaching 22% of mutants in both early- and late-onset
149 forms of HCC. The preeminent class of HCC-associated genetic defects was
150 epitomized by short deletions affecting notably the Wnt pathway. To the best
151 of our knowledge, this mutation spectrum is not only unprecedented for HCC
152 but also unique among solid tumors in which indels are usually monitored as a
153 marginal subset of genetic alterations, confirming further the distinctive
154 positioning of HCC in South America [22].

155

156 **Risk factors**

157 In the same study mentioned above from 2014, we addressed the
158 commentary made *a posteriori* first by Chan and colleagues in 2017 and then
159 by Debes in 2018 on the putative brunt of dietary aflatoxin intoxication in
160 early-age onset of HCC afflicting the patients in South America [17,20].

161 Among the 80 Peruvian patients analyzed, we found only one carrier of the
162 aflatoxin B1-induced R249S *TP53* gene mutation, who was, for the record, an
163 older individual [21,23]. Together with the evaluation of the dietary aflatoxin
164 risk factor, we also considered the possibility of a traditional misapplication of
165 medicinal plants that could contribute to the development of early-age onset
166 of HCC. Indeed, such self-medication disuse that enhances the risk of cancer
167 has been highlighted for *Aristolochia* plants in Chinese traditional medicine
168 [24]. We thus performed a cross-sectional study among 88 Peruvian patients
169 with liver cancer to document their herbal medicine practices [25]. Most of the
170 plant species cited in the survey were of common use in Peru, not being
171 reported hitherto to have carcinogenic potential. Moreover, we discarded, in
172 another preliminary report, the possibility in Peruvian HCC patients of chronic
173 infection with the liver fluke *Fasciola hepatica*, which is found to be endemic in
174 the Andean highlands and has previously been associated with liver
175 parenchymal insults [26,27].

176

177 **Histology**

178 Taking into account that a significant fraction of HCC patients from South
179 America do not present with full-fledged cirrhosis, we then decided to
180 comprehensively specify, from a histological point of view, the pathological
181 features of both tumor and non-tumor liver parenchymata of 50 HCC patients
182 from Peru [28]. Interestingly, younger HCC patients presented with virtually no
183 fibrolamellar carcinomas, which is a histotype occurring almost exclusively in
184 non-cirrhotic liver and allegedly earlier than age 40 [29]. In addition, a large
185 share of the liver tumors was steato-hepatitic HCC, a relatively rare variant

186 that is ordinarily associated with non-alcoholic fatty liver diseases and HCV-
187 related cirrhosis [30]. Above all, our survey emphasized the relatively healthy
188 status of the liver in Peruvian HCC patients. Tumors were arising mostly in
189 liver parenchyma with low to mild degrees of fibrosis; this figure is at odds
190 with the current view on the topic, as HCC in non-cirrhotic, non-fibrotic livers is
191 claimed to represent a small minority of the cases [31]. Similarly, the levels of
192 fatty liver and steatohepatitis (8%), as well as siderosis, were relatively low;
193 this latter observation refuting one of the hypotheses formulated by Ponzetto
194 and colleagues to explain the occurrence of early-age HCC among patients in
195 South America [19]. In addition, the micro-steatotic pattern observed in case
196 of infection with the genotype III of hepatitis Delta virus was conspicuously
197 absent from the series. However, a significant proportion of younger HCC
198 patients presented with a high density of clear cell foci of cellular alteration
199 within the non-tumor liver parenchyma [28]. From a morpho-histological
200 perspective, these hepatic foci are reminiscent of liver lesions observed in
201 rodent models that have been subjected to genotoxic chemicals [32]. The
202 exact burden of these clear cell foci and their potential role in liver
203 carcinogenesis has to be ascertained in HCC patients from South America.
204 Therefore, together with prevalent HBV infection, it is likely that the
205 intercession of hitherto poorly documented environmental, metabolic, or
206 infectious cofactors, such as alternative mycotoxins to aflatoxin B1, diabetes
207 mellitus, or even co-infection with *Helicobacter* spp., which is highly endemic
208 in the region [8,19,20,33].

209

210 **Role of hepatitis B virus**

211 As HBV is still suspected to be the prominent etiological agent and its
212 prevalence monitored serologically associates with younger HCC patients in
213 South America, we performed an in-depth molecular study of HBV infection in
214 65 HCC patients from Peru [34]. A narrow majority of individuals (51%) were
215 monitored HBsAg(+) and, thus, considered as genuinely infected at the onset
216 of the disease. Using an ultra-sensitive assay, HBV DNA was, however,
217 detected at a very low viral DNA burden in more than 80% of cases,
218 disclosing hence a substantial rate of occult HBV infections in HCC patients
219 [28,34,35]. A phylogenetic analysis of the viral sequences clustered every
220 isolate within the sub-genotype F1b, which is a clade encountered historically
221 in indigenous people of the Americas, notably in Alaska where the occurrence
222 of early-age HCC has been described as well [36–38]. Intriguingly, HBV DNA
223 sequence variations suggest an age-dependent restriction process, as viral
224 genomes in younger patients displayed significantly higher frequency of
225 mutations at di-pyrimidine sites (*i.e.*, TpT and CpC), which was until that time
226 an unprecedented feature in the HBV genome [34]. These findings sharply
227 contrast with the prevailing paradigm that relates higher HBV DNA loads with
228 early-age HCC development [39]. We made assumptions that, in Native
229 communities of the Americas, HBV-associated hepato-carcinogenesis might
230 depart substantially from that broadly observed in other populations [34].

231

232 **Clinical management**

233 Altogether, the clinical and biological singularities of HCC and associated
234 comorbidities observed in South America have some implications for the
235 management strategies for screening, detection, diagnosis, and prognosis of

236 HCC patients from the region, as well as the vigilance of the population at
237 risk. For instance, protocols used to screen for HBV infection, notably occult
238 ones, as well as to detect early HCC development in subjects at risk should
239 be tailored to the local situation. Furthermore, Trevisani and colleagues
240 asserted that non-cirrhotic, non-fibrotic HCC clinically represents a distinctive
241 nosological form of HCC with good amenability to liver resection even in
242 cases of major hepatectomy [31]. This observation was confirmed by our
243 review of the 253 Peruvian HCC patients who consecutively underwent a
244 curative hepatectomy at INEN between 1991 and 2011 [40]. In our hands, the
245 survival outcomes of liver resection observed were in good standing with
246 those recorded with liver transplantation in cirrhotic patients with an early-
247 stage tumor, despite the fact that the greatest part of the interventions
248 performed were major hepatectomies due to the size and topography of the
249 tumors exsected. This should be of great concern to the health policy-makers
250 and group of experts aiming to build a regional consensus for HCC prognosis
251 stratification and treatment guidelines and provide state-of-the-art
252 prescriptions for local physicians and scientists, such as the Latin American
253 Association for the Study of the Liver (LAASL) [41].

254

255 **Concluding remark**

256 Finally, another uncertainty concerns the magnitude of the phenomenon
257 frequently observed in Peru; as to whether it is restricted to the Peruvian
258 Andean communities or also occurs in other human populations, perhaps to a
259 lesser degree. The observations made by Debes and colleagues confirm our
260 original findings at an upper South American continental level [17,18].

261 Nevertheless, the occurrence of early-age forms of HCC in Alaskan Native
262 people, 10,000 km distant from the indigenous communities of Peru but
263 infected with the very same HBV clade, leads to speculation about the
264 eventuality of a widespread, particular hepato-carcinogenic process shared
265 among all populations with Americas' indigenous ancestry component
266 [16,34,37,42].

267

268 **Disclosure of interest:** The authors declare that they have no competing
269 interest.

270

271 **Acknowledgements:** The authors are grateful to Elizabeth Elliott, Brian
272 Gadd, and Joshua Lee Halford for their valuable editorial assistance.

273

274 **Funding:** This work was supported by the French National Alliance for Life
275 Sciences and Health [grant number ENV201408]; the French National League
276 Against Cancer, Paris, France; and the French National Research Institute for
277 Sustainable Development.

278

279 **References**

- 280 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global
281 cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
282 worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018.
283 doi:10.3322/caac.21492.
- 284 [2] Llovet JM, Zucman Rossi J, Pikarsky E, Sangro B, Schwartz M,
285 Sherman M, et al. Hepatocellular carcinoma. *Nat Rev Dis Primer*
286 2016;2:16018. doi:10.1038/nrdp.2016.18.
- 287 [3] Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions
288 according to the Human Development Index (2008-2030): a population-
289 based study. *Lancet Oncol* 2012;13:790–801. doi:10.1016/S1470-
290 2045(12)70211-5.
- 291 [4] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et
292 al. Cancer incidence and mortality worldwide: sources, methods and
293 major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359-386.
294 doi:10.1002/ijc.29210.
- 295 [5] Soerjomataram I, Lortet Tieulent J, Parkin DM, Ferlay J, Mathers C,
296 Forman D, et al. Global burden of cancer in 2008: a systematic analysis
297 of disability-adjusted life-years in 12 world regions. *Lancet*
298 2012;380:1840–50. doi:10.1016/S0140-6736(12)60919-2.
- 299 [6] Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The
300 contributions of hepatitis B virus and hepatitis C virus infections to
301 cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006;45:529–38.
302 doi:10.1016/j.jhep.2006.05.013.

- 303 [7] Kucukcakan B, Hayrulai Musliu Z. Challenging role of dietary aflatoxin
304 B1 exposure and hepatitis B infection on risk of hepatocellular
305 carcinoma. *Open Access Maced J Med Sci* 2015;3:363–9.
306 doi:10.3889/oamjms.2015.032.
- 307 [8] Li X, Wang X, Gao P. Diabetes mellitus and risk of hepatocellular
308 carcinoma. *BioMed Res Int* 2017;2017:5202684.
309 doi:10.1155/2017/5202684.
- 310 [9] Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes,
311 mechanism of progression and biomarkers. *Curr Chem Genomics Transl*
312 *Med* 2018;12:9–26. doi:10.2174/2213988501812010009.
- 313 [10] Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a
314 review and a point of view. *World J Gastroenterol* 2014;20:15943–54.
315 doi:10.3748/wjg.v20.i43.15943.
- 316 [11] Bray F, Piñeros M. Cancer patterns, trends and projections in Latin
317 America and the Caribbean: a global context. *Salud Publica Mex*
318 2016;58:104–17.
- 319 [12] Wong MCS, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FDH, et al.
320 International incidence and mortality trends of liver cancer: a global
321 profile. *Sci Rep* 2017;7:45846. doi:10.1038/srep45846.
- 322 [13] Donayre M, Bussalleu A, Berríos J, Cok J. Carcinoma primario de
323 hígado en el Hospital Nacional Cayetano Heredia (Enero 1969 - Abril
324 1997). Hallazgos clínicos y de laboratorio. *Rev Gastroenterol Peru*
325 1999;19:15–25.
- 326 [14] Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, et al.

- 327 Impact of sex on the survival of patients with hepatocellular carcinoma: a
328 Surveillance, Epidemiology, and End Results analysis. *Cancer*
329 2014;120:3707–16. doi:10.1002/cncr.28912.
- 330 [15] Ruiz E, Sanchez J, Celis J, Payet E, Berrospi F, Chavez I, et al.
331 Resultados a corto y largo plazo de la resección hepática por
332 hepatocarcinoma. Análisis de 232 resecciones consecutivas. *Rev*
333 *Gastroenterol Peru* 2007;27:223–37.
- 334 [16] Bertani S, Pineau P, Loli S, Moura J, Zimic M, Deharo E, et al. An
335 atypical age-specific pattern of hepatocellular carcinoma in Peru: a
336 threat for Andean populations. *PLOS One* 2013;8:e67756.
337 doi:10.1371/journal.pone.0067756.
- 338 [17] Chan AJ, Balderramo D, Kikuchi L, Ballerga EG, Prieto JE, Tapias M, et
339 al. Early age hepatocellular carcinoma associated with hepatitis B
340 infection in South America. *Clin Gastroenterol Hepatol* 2017;15:1631–2.
341 doi:10.1016/j.cgh.2017.05.015.
- 342 [18] Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E,
343 Prieto JE, et al. Hepatocellular carcinoma in South America: evaluation
344 of risk factors, demographics and therapy. *Liver Int* 2018;38:136–43.
345 doi:10.1111/liv.13502.
- 346 [19] Ponzetto A, Diella FA, Holton J. Aetiology of hepatocellular carcinoma in
347 South America. *Liver Int* 2018;38:956–7. doi:10.1111/liv.13703.
- 348 [20] Debes JD. Early hepatocellular carcinoma in South America: what is to
349 blame? *Liver Int* 2018;38:957–8. doi:10.1111/liv.13717.
- 350 [21] Marchio A, Bertani S, Rojas Rojas T, Doimi F, Terris B, Deharo E, et al.

- 351 A peculiar mutation spectrum emerging from young Peruvian patients
352 with hepatocellular carcinoma. PLOS One 2014;9:e114912.
353 doi:10.1371/journal.pone.0114912.
- 354 [22] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler
355 KW. Cancer genome landscapes. Science 2013;339:1546–58.
356 doi:10.1126/science.1235122.
- 357 [23] Mao R, Liu J, Liu G, Jin S, Xue Q, Ma L, et al. Whole genome
358 sequencing of matched tumor, adjacent non-tumor tissues and
359 corresponding normal blood samples of hepatocellular carcinoma
360 patients revealed dynamic changes of the mutations profiles during
361 hepatocarcinogenesis. Oncotarget 2017;8:26185–99.
362 doi:10.18632/oncotarget.15428.
- 363 [24] Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et
364 al. Urothelial carcinoma associated with the use of a Chinese herb
365 (*Aristolochia fangchi*). N Engl J Med 2000;342:1686–92.
366 doi:10.1056/NEJM200006083422301.
- 367 [25] Rojas Rojas T, Bourdy G, Ruiz E, Cerapio JP, Pineau P, Gardon J, et al.
368 Herbal medicine practices of patients with liver cancer in Peru: a
369 comprehensive study toward integrative cancer management. Integr
370 Cancer Ther 2018;17:52–64. doi:10.1177/1534735416681642.
- 371 [26] Machicado C, Bertani S, Herrera Velit P, Espinoza J, Ruiz E, Marcos L.
372 Negative serology of *Fasciola hepatica* infection in patients with liver
373 cancer in Peru: a preliminary report. Rev Soc Bras Med Trop
374 2018;51:231–3. doi:10.1590/0037-8682-0180-2017.

- 375 [27] Cabada MM, Morales ML, Webb CM, Yang L, Bravenec CA, Lopez M, et
376 al. Socioeconomic factors associated with *Fasciola hepatica* infection
377 among children from 26 communities of the Cusco region of Peru. *Am J*
378 *Trop Med Hyg* 2018. doi:10.4269/ajtmh.18-0372.
- 379 [28] Cano L, Cerapio JP, Ruiz E, Marchio A, Turlin B, Casavilca S, et al.
380 Liver clear cell foci and viral infection are associated with non-cirrhotic,
381 non-fibrolamellar hepatocellular carcinoma in young patients from South
382 America. *Sci Rep* 2018;8:9945. doi:10.1038/s41598-018-28286-0.
- 383 [29] Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD.
384 Clinicopathologic features and survival in fibrolamellar carcinoma:
385 comparison with conventional hepatocellular carcinoma with and without
386 cirrhosis. *Mod Pathol* 2005;18:1417–23.
387 doi:10.1038/modpathol.3800449.
- 388 [30] Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitz JH.
389 Steatohepatic hepatocellular carcinoma (SH-HCC): a distinctive
390 histological variant of HCC in hepatitis C virus-related cirrhosis with
391 associated NAFLD/NASH. *Am J Surg Pathol* 2010;34:1630–6.
392 doi:10.1097/PAS.0b013e3181f31caa.
- 393 [31] Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M.
394 Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. *Dig Liver*
395 *Dis* 2010;42:341–7. doi:10.1016/j.dld.2009.09.002.
- 396 [32] Ribback S, Calvisi DF, Cigliano A, Sailer V, Peters M, Rausch J, et al.
397 Molecular and metabolic changes in human liver clear cell foci resemble
398 the alterations occurring in rat hepatocarcinogenesis. *J Hepatol*

- 399 2013;58:1147–56. doi:10.1016/j.jhep.2013.01.013.
- 400 [33] Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of *Helicobacter pylori*
401 infection. *Helicobacter* 2014;19 Suppl 1:1–5. doi:10.1111/hel.12165.
- 402 [34] Marchio A, Cerapio JP, Ruiz E, Cano L, Casavilca S, Terris B, et al.
403 Early-onset liver cancer in South America associates with low hepatitis B
404 virus DNA burden. *Sci Rep* 2018;8:12031. doi:10.1038/s41598-018-
405 30229-8.
- 406 [35] Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert
407 operation. *J Viral Hepat* 2010;17:1–15. doi:10.1111/j.1365-
408 2893.2009.01245.x.
- 409 [36] von Meltzer M, Vásquez S, Sun J, Wendt UC, May A, Gerlich WH, et al.
410 A new clade of hepatitis B virus subgenotype F1 from Peru with unusual
411 properties. *Virus Genes* 2008;37:225–30. doi:10.1007/s11262-008-
412 0261-x.
- 413 [37] Gounder PP, Bulkow LR, Snowball M, Negus S, Spradling PR,
414 McMahon BJ. Hepatocellular carcinoma risk in Alaska Native children
415 and young adults with hepatitis B virus: retrospective cohort analysis. *J*
416 *Pediatr* 2016;178:206–13. doi:10.1016/j.jpeds.2016.08.017.
- 417 [38] Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ,
418 Homan CE, et al. Hepatitis B virus genotypes in Alaska Native people
419 with hepatocellular carcinoma: preponderance of genotype F. *J Infect*
420 *Dis* 2007;195:5–11. doi:10.1086/509894.
- 421 [39] Chen CJ, Yang HI, Iloeje UH, REVEAL-HBV Study Group. Hepatitis B
422 virus DNA levels and outcomes in chronic hepatitis B. *Hepatol Baltim Md*

423 2009;49:S72-84. doi:10.1002/hep.22884.

424 [40] Ruiz E, Rojas Rojas T, Berrospi F, Chávez I, Luque C, Cano L, et al.
425 Hepatocellular carcinoma surgery outcomes in the developing world: a
426 20-year retrospective cohort study at the National Cancer Institute of
427 Peru. *Heliyon* 2016;2:e00052. doi:10.1016/j.heliyon.2015.e00052.

428 [41] Méndez Sánchez N, Ridruejo E, Alves de Mattos A, Chávez Tapia NC,
429 Zapata R, Paraná R, et al. Latin American Association for the Study of
430 the Liver (LAASL) clinical practice guidelines: management of
431 hepatocellular carcinoma. *Ann Hepatol* 2014;13 Suppl 1:S4-40.

432 [42] Hayashi S, Khan A, Simons BC, Homan C, Matsui T, Ogawa K, et al. A
433 novel association between core mutations in hepatitis B virus genotype
434 F1b and hepatocellular carcinoma in Alaskan Native People. *Hepatology*
435 2018. doi:10.1002/hep.30111.

436